LEOCLAN Co.,Ltd.
Notice Regarding Revision of Full-Year Earnings Forecast
Full-year consolidated earnings forecast for the fiscal year ending September 2026 revised upward. Revenue is raised from previous forecast of 44,500 million yen to 48,000 million yen; operating income from 680 million yen to 890 million yen; ordinary income from 610 million yen to 820 million yen; net income attributable to owners of parent from 230 million yen to 400 million yen. Increases: revenue +3,500 million yen; profit items +210 million yen and +170 million yen. Reasons: expanded demand for medical device sales and contribution from the Fascia Group subsidiary. Prior year results: revenue 21,489 million yen; net income 152 million yen.
Key Figures
- Revenue: 48,000 million yen (previous forecast +3,500 million yen, +7.9%)
- Operating income: 890 million yen (previous forecast +210 million yen, +30.9%)
- Ordinary income: 820 million yen (previous forecast +210 million yen, +34.4%)
- Net income attributable to owners of parent: 400 million yen (previous forecast +170 million yen, +73.9%)
- Earnings per Share: 67.55 yen (previous forecast Unknown)
AI要約
Overview of earnings forecast revision
The full-year consolidated earnings forecast for the fiscal year ending September 2026 released today shows higher revenue than the previous forecast, with operating income, ordinary income, and net income also revised upward. The main drivers are stronger-than-expected demand for medical devices, sales activity for large medical devices and medical information systems, and contribution from the Fascia Group subsidiary in minimal-invasive medical devices and hearing aid sales.
Outlook and impact
While revenue and profit are expected to beat on the back of new demand, uncertainties such as healthcare industry labor shortages and rising costs persist, and actual results will depend on future market trends and cost management. The key is whether the factors cited in the revision sustain, and attention should be paid to hospital equipment renewal needs and market response for hearing aids and minimally invasive devices.
LEOCLAN Co.,Ltd.
Company overview · Stock price · Financial data · All IR
